Evidence map›Paper›PMID 39337509›Full record

ArticleInternational journal of molecular sciences2024

Chemokinergic and Dopaminergic Signalling Collaborates through the Heteromer Formed by CCR9 and Dopamine Receptor D5 Increasing the Migratory Speed of Effector CD4

Javier Campos, Francisco Osorio-Barrios, Felipe Villanelo, Sebastian E Gutierrez-Maldonado, Pablo Vargas, Tomás Pérez-Acle, Rodrigo Pacheco

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Reversing Dysfunction of CCR9Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Javier CamposCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Huechuraba 8580704, Santiago, Chile.ORCID 0000-0002-6420-0744
Francisco Osorio-BarriosGut Microbiology, Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 25, 3001 Bern, Switzerland.
Felipe VillaneloCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Huechuraba 8580704, Santiago, Chile.ORCID 0000-0001-7901-172X
Sebastian E Gutierrez-MaldonadoCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Huechuraba 8580704, Santiago, Chile.
Pablo VargasInstitut Curie, PSL Research University, CNRS, UMR144, F-75005 Paris, France.
Tomás Pérez-AcleCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Huechuraba 8580704, Santiago, Chile.ORCID 0000-0002-3769-390X
Rodrigo PachecoCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Huechuraba 8580704, Santiago, Chile.ORCID 0000-0001-8057-9806

Funding

Agencia Nacional de Investigación y Desarrollo FB210008Agencia Nacional de Investigación y Desarrollo FONDECYT-1210013Agencia Nacional de Investigación y Desarrollo FONDECYT-3200937
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBDs) involve chronic inflammation of the gastrointestinal tract, where effector CD4

Indexed as

CD4-Positive T-LymphocytesIntestinal MucosaReceptors, CCRReceptors, Dopamine D5Signal TransductionCell MovementColonDopamineHumansInflammatory Bowel DiseasesCC chemokine receptor 9DopamineDRD5 protein, humanReceptors, CCRReceptors, Dopamine D5chemokinesdopamineG protein-coupled receptorsheteromersinflammatory bowel diseasesT-cell migration

Identifiers

PMID39337509
PMCPMC11432204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.